Is ELAC2 p.Pro493= (c.1479G>C) pathogenic?

ELAC2 p.Pro493= (c.1479G>C) is classified Benign in ELAC2 (ClinVar, Multiple submitters, 5 submitters; last evaluated 2026-02-03). Low-frequency (popmax 2.86%, afr); Associated with combined oxidative phosphorylation defect type 17.

How common is ELAC2 p.Pro493= (c.1479G>C) in the general population?

ELAC2 p.Pro493= (c.1479G>C) is low-frequency (popmax 2.86%, afr) (gnomAD).

ELAC2 p.Pro493=

Q: What condition is associated with ELAC2 p.Pro493= (c.1479G>C)?

ELAC2 p.Pro493= (c.1479G>C) is associated with combined oxidative phosphorylation defect type 17, prostate cancer, hereditary, 2 (ClinVar).

Q: How is Combined oxidative phosphorylation defect type 17 inherited?

Typically Autosomal recessive (Orphanet). A genetic counselor can assess individual risk for a family.

c.1479G>C · rs140335642 · VCV241270

Benign Multiple submitters

Classification

Benign

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 5 submitters

gnomAD v4.1

Rare

low-frequency (popmax 2.86%, afr)

Conditions

combined oxidative phosphorylation defect type 17

Computational evidence

Protein change
Missense predictors do not apply to this variant type; conservation carries the signal.
REVEL	0.068	moderately benign-leaning
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP -6	GERP -4.1
Overall
CADD	0.995	PHRED · no single calibrated threshold — expert panels disagree

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 2.86% African / African-American · 2,143/75,030 alleles

Filtering AF 2.76% ClinGen BA1/BS1 input FAF95, joint · FAF99 2.71%

Overall 0.157% 2,527/1,614,176 alleles · low-frequency

Ancestry group	Frequency	1 in
African / African-Americangrpmax	2.86%	35
Middle Eastern	0.429%	233
Admixed American	0.253%	395
Remaining individualsnot grpmax-eligible	0.246%	406
South Asian	0.00659%	15,180
East Asian	0.00446%	22,441
European (non-Finnish)	0.00373%	26,819

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: ELAC2
Protein: p.Pro493=
Coding: c.1479G>C
MANE Select: NM_018127
dbSNP: rs140335642
Type: single nucleotide variant
Location: chr17:12998453 (GRCh38)
Gene constraint: LOEUF 1.02 · pLI <0.01 (gnomAD)
Structure: AlphaFold pLDDT 82.81 · 10 PDB

Full ELAC2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

combined oxidative phosphorylation defect type 17 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: prostate cancer, hereditary, 2

For Combined oxidative phosphorylation defect type 17 (Orphanet):

Inheritance: Autosomal recessive
Onset: Infancy, Neonatal

Similar variants

ELAC2 p.Pro493Arg Uncertain significance ★ ⚠ same residue
ELAC2 p.Pro493Leu Likely pathogenic ★ same residue
ELAC2 c.1080-1G>C Likely pathogenic ★★ same condition
ELAC2 c.1423+1G>A Pathogenic ★★ same condition
ELAC2 c.1908+1G>A Likely pathogenic ★★ same condition
ELAC2 c.245+2T>A Pathogenic/Likely pathogenic ★★ same condition
ELAC2 p.Arg497Ter Pathogenic/Likely pathogenic ★★ same condition
ELAC2 p.Gln18Ter Pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/elac2-p-pro493 (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown